Search results
First Trust Advisors LP Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 2 days agoFirst Trust Advisors LP grew its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% in the fourth quarter, according to its most recent filing with the Securities ...
AstraZeneca’s Lung, Breast Cancer Drugs Markedly Slow Disease
Bloomberg· 6 days agoAstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 19 hours agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
Nucleus RadioPharma secures Series A investment from AstraZeneca
BioPharma-Reporter· 2 days agoThe investment from AstraZeneca marks a strategic move to further expand Nucleus's capabilities in developing targeted radiotherapies and theranostics, aimed at making cancer ...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 5 days agoAstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...
AstraZeneca finalizes Fusion Pharmaceuticals buyout By Investing.com
Investing.com· 4 days agoThis move is aligned with AstraZeneca (NASDAQ:AZN)'s strategy to advance cancer therapy by focusing...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 19 hours agoRecap of the Week’s Most Important Stories Lilly’s CFO Departs: Lilly’s executive vice president and...
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 3 days agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 3 days agoOsimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the time patients live without their cancer worsening, offering the first effective ...